The Securities and Exchange Commission has not necessarily reviewed the information in this filing and has not determined if it is accurate and complete.
The reader should not assume that the information is accurate and complete.

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
FORM 13F

FORM 13F INFORMATION TABLE

OMB APPROVAL
OMB Number: 3235-0006
Estimated average burden
hours per response: 23.8

COLUMN 1 COLUMN 2 COLUMN 3 COLUMN 4 COLUMN 5 COLUMN 6 COLUMN 7 COLUMN 8
VALUE SHRS OR SH/ PUT/ INVESTMENT OTHER VOTING AUTHORITY
NAME OF ISSUER TITLE OF CLASS CUSIP (x$1000) PRN AMT PRN CALL DISCRETION MANAGER SOLE SHARED NONE
ACURA PHARMACEUTICALS INC COM 00509L802 352 1,956,397 SH   SOLE   1,956,397 0 0
AXOGEN INC COM 05463X106 57,699 2,739,751 SH   SOLE   2,739,751 0 0
CATALYST COM 14888D109 640 78,622 SH   SOLE   78,622 0 0
CORIUM COM 21887L107 3,488 0 SH   SOLE   0 0 0
ENDOLOGIX INC COM 29266S106 1,293 1,257,468 SH   SOLE   1,257,468 0 0
EYEPOINT COM 74440J101 75,018 41,909,219 SH   SOLE   41,909,219 0 0
MEDICINOVA INC COM 58468P206 9,691 1,170,370 SH   SOLE   1,170,370 0 0
REVANCE THERAPEUTICS INC COM 761330109 52,671 3,342,047 SH   SOLE   3,342,047 0 0